Compare Globus Medical Inc. Class A Common Stock (GMED) vs Keel Infrastructure Corp. Common Stock (KEEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Keel Infrastructure Corp. Common Stock — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Keel Infrastructure Corp. Common Stock trades at $2.48 (market cap $1.77B). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 5.8× Keel Infrastructure Corp. Common Stock's market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, Keel Infrastructure Corp. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Keel Infrastructure Corp. Common Stock for 3 Days on average.
| GMED | KEEL | |
|---|---|---|
Market Cap | $10.25B | $1.77B |
Volume | 1,108,124 | 34,111,650 |
Sector | Health | Technology |
52-Week High | $96.82 | $6.66 |
52-Week Low | $58.33 | $1.71 |
Typical Hold Time | 0 Days | 3 Days |
Enterprise Value | $9.76B | $2.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
KEEL trades at $2.87, down 2.71% on the day, reflecting a bearish technical trend amid weak financial performance. The company reported a net loss of $208.51M on $229.28M revenue in 2025, with negative profit margins and cash flow from operations. Despite this, analyst consensus is unanimously bullish with a $6.25 price target, citing progress in its HPC and AI data center strategy, including a recent partnership with PowerSecure for its Moses Lake campus.
The outlook hinges on successful execution of its data center pivot, offering significant upside if leasing targets are met, but high execution risk and persistent losses pose substantial threats to shareholder value. Liquidity remains supported by financing activities, yet profitability challenges and competitive pressures require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Keel Infrastructure Corp. Common Stock
Keel Infrastructure develops and owns digital and energy infrastructure for high-performance computing workloads. Its assets include data centers and power infrastructure that support AI computing.
Read more on KEEL →
